🔥 Gate Square Event: #PostToWinNIGHT 🔥
Post anything related to NIGHT to join!
Market outlook, project thoughts, research takeaways, user experience — all count.
📅 Event Duration: Dec 10 08:00 - Dec 21 16:00 UTC
📌 How to Participate
1️⃣ Post on Gate Square (text, analysis, opinions, or image posts are all valid)
2️⃣ Add the hashtag #PostToWinNIGHT or #发帖赢代币NIGHT
🏆 Rewards (Total: 1,000 NIGHT)
🥇 Top 1: 200 NIGHT
🥈 Top 4: 100 NIGHT each
🥉 Top 10: 40 NIGHT each
📄 Notes
Content must be original (no plagiarism or repetitive spam)
Winners must complete Gate Square identity verification
Gat
Anglikan: The only innovative drug project currently under research is ALK-N001.
Golden Ten Data on June 9, Anglikang issued a change announcement, the company’s shares for 2 consecutive trading days closing price deviation of more than 20%, belongs to the abnormal fluctuation of stock trading. The company’s current innovative drug project under development is only ALK-N001, which obtained the drug clinical trial approval notice in April 2025 and is still in the phase I clinical trial stage as of the disclosure date of this announcement. The R&D of innovative drugs has the characteristics of long cycle, large investment and high uncertainty, so investors should pay attention to investment risks.